FINWIRES · TerminalLIVE
FINWIRES

Japan Logistics Fund to Expand Investment Scope With New Asset Classes

-- Mitsui & Co., Logistics Partners, the asset manager of Japan Logistics Fund (TYO:8967), has resolved to change the REIT's asset management guideline, effective April 23.

The changes aim to expand the REIT's investment opportunities by adding new asset classes to its real estate-related assets, including limited partnership interests in investment businesses that primarily invest in real estate-type assets, as well as monetary claims.

Correspondingly, the revised guideline will update the REIT's portfolio construction policy and introduce new provisions for confirming matters related to the acquisition of these expanded asset types.

The change is subject to shareholder approval of partial amendments to the Articles of Incorporation at the 16th general unitholders' meeting on that same day, according to a Tokyo bourse filing on Monday.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062